Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 14/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8428972 | 0.98 | EPHX1 (0.68) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL8429147 | 0.89 | EPHX1 (0.65) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL8432151 | 0.87 | EPHX1 (0.68) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL9750349 | 0.85 | EPHX1 (0.86) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL19420509 | 0.85 | EPHX1 (0.86) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL14423989 | 0.81 | EPHX1 (0.87) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL8432351 | 0.80 | EPHX1 (0.60) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL5020902 | 0.80 | EPHX1 (0.90) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL15224138 | 0.80 | EPHX1 (0.68) | EPHX1EPHX2KDM4EALDH1A1 | |
| SCHEMBL1193592 | 0.80 | EPHX1 (0.97) | EPHX1EPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1851218-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS | 3M Innovative Properties Company (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006091567-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-0937069-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5877321-A | NEUROKININ RECEPTOR | SANOFI (FR) | 1999-03-02 | — | — | US | disclosed |
| US-5773620-A | Quaternary ammonium salts of aromatic amine compounds, their preparation and pharmaceutical compositions in which they are present | ELF SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5770735-A | Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present | ELF SANOFI (FR) | 1998-06-23 | — | — | US | disclosed |
| WO-1998018788-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-05-07 | — | — | WO | disclosed |
| US-5712288-A | TACHYKININ ANTAGONIST, ANTIINFLAMMATORY, ANTIALLERGEN | SANOFI (FR) | 1998-01-27 | — | — | US | disclosed |
| US-5411971-A | N-alkylenepiperidino compounds, their enantiomers and pharmaceutical compositions | ELF SANOFI (FR) | 1995-05-02 | — | — | US | disclosed |
| US-5350852-A | Neurokinin A receptor antagonist | SANOFI (FR) | 1994-09-27 | — | — | US | disclosed |
| US-5340822-A | Substance P, neurokinin antagonists | ELF SANOFI (FR) | 1994-08-23 | — | — | US | disclosed |
| US-5317020-A | Neurokinin receiver antagonist as antiinflammatory agents | SANOFI (FR) | 1994-05-31 | — | — | US | disclosed |
| US-5300648-A | Analgesics, antiinflammatory agents | SOCIETE ANONYME: ELF SANOFI (FR) | 1994-04-05 | — | — | US | disclosed |
| US-5254595-A | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them | ELF SANOFI (FR) | 1993-10-19 | — | — | US | disclosed |
| US-5236921-A | Administrering for treatment of neutrogenic inflammation of the respiratory trart | SANOFI (FR) | 1993-08-17 | — | — | US | disclosed |
| EP-0200915-B1 | AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
| US-4863949-A | CARDIOVASCULAR DISORDER TREATMENT | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0280951-A1 | Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates | Roche Diagnostics GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | EPHX1 569/4885EPHX2 864/4885KDM4E 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.